Treatment News

Dyax Corp. to Participate in the Leerink Swann Rare Disease Roundtable

1.7 from 3 votes
Tuesday, October 01, 2013

Learn more about:

Access Programs

Dyax Corp., a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders announced today that Gustav Christensen President and Chief Executive Officer and Burt Adelman M.D. Executive Vice President and Chief Medical Officer will participate in the Leerink Swann Rare Disease Roundtable on Wednesday October 2 2013 at Le Parker Meridien in New York City and are scheduled to present at 9:00 AM ET that day. Mr. Christensen and Dr. Adelman will give an update on the outlook for the KALBITOR® (ecallantide) business as well as discuss DX-2930 and the Licensing and Funded Research Program.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at The webcast will also be available on the Dyax website for a limited period of time following the conference.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business DX-2930 and the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and since February 2010 has been selling it in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older. Outside the United States the Company has established partnerships to obtain regulatory approval and commercialize KALBITOR in certain markets and is evaluating opportunities in others.

The Company is developing products to expand its angioedema portfolio including a therapeutic candidate DX-2930 for the prophylactic treatment of HAE and a diagnostic test to identify plasma kallikrein-mediated disorders. In August 2013 Dyax began a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930 in healthy subjects.

KALBITOR and DX-2930 were identified using Dyax's patented phage display technology which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees which currently includes 13 revenue generating product candidates in various stages of clinical development including three in Phase 3 trials.

For additional information about Dyax please visit

For additional information about KALBITOR including full prescribing information please visit


This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax's current expectations beliefs assumptions estimates forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks uncertainties and assumptions which are difficult to predict. Therefore actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect future performance include the risks that: DX-2930 may not show sufficient therapeutic effect or an acceptable safety profile in clinical trials or could take longer to gain regulatory approval than Dyax expects or may never gain approval; others may develop products superior to KALBITOR or DX-2930; KALBITOR and/or DX-2930 may not gain market acceptance; Dyax is dependent on the expertise effort priorities and contractual obligations of third parties in the manufacture marketing sales and distribution of KALBITOR and DX-2930; and other risk factors described or referred to in Item 1A "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release and Dyax undertakes no obligations to update or revise these statements except as may be required by law.




Source: Dyax Corp
1.7 from 3 votes
Free Newsletter
Related Videos
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma
by Dr. Jules Richard Kemadjou